1. Circulating biomarkers of fibrosis and cardioversion of atrial fibrillation: A prospective, controlled cohort study

Clinical Biochemistry, 2017, 50(1-2) p. 11

DOI: 10.1016/j.clinbiochem.2016.09.008

Citations as recorded by:

2. Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation

Journal of Arrhythmia, 2017, 33(5) p. 469

DOI: 10.1016/j.joa.2017.05.003

Citations as recorded by:

3. Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review

Med Sci Monit Basic Res, 2017, 23 p. 58

DOI: 10.12659/MSMBR.902557

Citations as recorded by:

4. Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis

Med Sci Monit Basic Res, 2017, 23 p. 179

DOI: 10.12659/MSMBR.903320

Citations as recorded by:

5. Response to the letter to editor: Galectin-3 and atrial fibrillation

International Journal of Cardiology, 2017, 229 p. 2

DOI: 10.1016/j.ijcard.2016.12.006

Citations as recorded by:

6. Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke

BioMed Research International, 2017, 2017 p. 1

DOI: 10.1155/2017/8153024

Citations as recorded by:

7. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study

American Heart Journal, 2017, 192 p. 19

DOI: 10.1016/j.ahj.2017.07.001

Citations as recorded by:

8. Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring

J Endocrinol Invest,

DOI: 10.1007/s40618-017-0729-4

Citations as recorded by:

9. Effects of telmisartan on paroxysmal atrial fibrillation in hypertensive patients.

Year: 2017

Citations as recorded by:

10. Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter …

Year: 2017

Citations as recorded by:

11. The emerging role of galectins in cardiovascular disease

Vascular Pharmacology, 2016, 81 p. 31

DOI: 10.1016/j.vph.2016.02.006

Citations as recorded by:

12. The serum matrix metalloproteinase-9 level is an independent predictor of recurrence after ablation of persistent atrial fibrillation

Clinics (Sao Paulo), 2016, 71 p. 251

DOI: 10.6061/clinics/2016(05)02

Citations as recorded by:

13. Association of β1-Adrenergic, M2-Muscarinic Receptor Autoantibody with Occurrence and Development of Nonvalvular Atrial Fibrillation

Pacing and Clinical Electrophysiology, 2016, 39(12) p. 1379

DOI: 10.1111/pace.12976

Citations as recorded by:

14. Association of MMPs and TIMPs With the Occurrence of Atrial Fibrillation: A Systematic Review and Meta-analysis

Canadian Journal of Cardiology, 2016, 32(6) p. 803

DOI: 10.1016/j.cjca.2015.08.001

Citations as recorded by:

15. Chronic Osteomyelitis and Atrial Fibrillation: Revisiting the Link Between Inflammation Burden and Arrhythmia

Canadian Journal of Cardiology, 2016, 32(12) p. 1366

DOI: 10.1016/j.cjca.2016.05.002

Citations as recorded by:

16. New onset atrial fibrillation is associated with elevated galectin-3 levels

International Journal of Cardiology, 2016, 223 p. 48

DOI: 10.1016/j.ijcard.2016.08.172

Citations as recorded by:

17. Galectin-3: A potential new target for upstream therapy of atrial fibrillation

International Journal of Cardiology, 2016, 203 p. 1131

DOI: 10.1016/j.ijcard.2015.09.058

Citations as recorded by:

18. Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation

Heart Failure Clinics, 2016, 12(2) p. 309

DOI: 10.1016/j.hfc.2015.08.024

Citations as recorded by:

19. New onset atrial fibrillation is associated with elevated galectin-3 levels.

Year: 2016

Citations as recorded by:

20. Association of β1‐Adrenergic, M2‐Muscarinic Receptor Autoantibody with Occurrence and Development of Nonvalvular Atrial Fibrillation

Year: 2016

Citations as recorded by:

21. Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran

Year: 2016

Citations as recorded by:

22. Association of Neutrophil-Lymphocyte Ratio with the Presence and Severity of Degenerative Aortic Valve Stenosis

Year: 2016

Citations as recorded by:

23. Role of Inflammation in Atrial Fibrillation Pathophysiology and Management

Circ J, 2015, 79(3) p. 495

DOI: 10.1253/circj.CJ-15-0138

Citations as recorded by:

24. Galectin-3 in atrial fibrillation: Simple bystander, player or both?

Clinical Biochemistry, 2015, 48(12) p. 818

DOI: 10.1016/j.clinbiochem.2015.04.021

Citations as recorded by:

25. Usefulness of Neutrophil/Lymphocyte Ratio as a Predictor of Atrial Fibrillation: A Meta-analysis

Archives of Medical Research, 2015, 46(3) p. 199

DOI: 10.1016/j.arcmed.2015.03.011

Citations as recorded by:

26. Молекулярные механизмы фибрилляции предсердий: в поиске «идеального» маркера

Year: 2015

Citations as recorded by:

27. Disease Focused Approach on Fibrosis Biomarkers in Cardiovascular Health

Year: 2015

Citations as recorded by:

28. Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation

Cardiology Clinics, 2014, 32(4) p. 637

DOI: 10.1016/j.ccl.2014.07.004

Citations as recorded by:

29. Association between Reversal in the Expression of Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel and Age-Related Atrial Fibrillation

Med Sci Monit, 2014, 20 p. 2292

DOI: 10.12659/MSM.892505

Citations as recorded by:

30. The fibrosis biomarkers procollagen type III, N-terminal propeptide and transforming growth factor β1 as foes for patients with atrial fibrillation

American Heart Journal, 2014, 168(4) p. e15

DOI: 10.1016/j.ahj.2014.07.004

Citations as recorded by: